Developer of a diagnostic test platform designed to detect cancer at an asymptomatic stage. The company specializes in providing clinical diagnostic tools that seek to recognize early cancer detection in clinical examinations with its microRNA quantification test, enabling healthcare professionals to identify cancer at early stages.
Developer of a fall prevention monitoring system designed to offer remote patient care. The company’s platform utilizes ceiling-mounted smart cameras with AI to continuously monitor patients for bed exit activity, enabling hospital sectors to monitor real-time activity and ensure the quality of care for patients.
Developer of magnetic muscle activation technology designed to delegate seniors to active and healthy lives. The company’s product is tuned magnetic fields that activate mitochondria, the cellular powerhouse found deep within the muscle, enabling elderly, frail, or recovering persons who find exercise challenging the healthy benefits of muscle activation, without requiring movement of muscles from the inside without physical movement, enabling the elderly with better balance and mobility.
Operator of an artificial intelligence-driven digital health platform and wearables company designed to enable and empower people for mobility. The company offers services that are focused on reducing the burden of musculoskeletal conditions and a continuous monitoring device for the knee joint which uses artificial intelligence technology for digital MSK (musculoskeletal) assessment and therapy, enabling the patients with pre-consultation assessments and real-time exercise guidance and feedback.
Developer of an artificial intelligence-driven technology designed for the detection of breast cancer. The company’s technology offers an artificial intelligence model for mammograms for advanced breast cancer screening to help detect abnormal lesions, estimate one’s risk of developing breast cancer, and automatically generate a radiology report for use by clinicians, enabling medical professionals in the healthcare system to address the increasing cases of breast cancer better and reduce false-positive rates. FathomX is a Digital Health AI spin-off company from the National University of Singapore and National University Health System and is the brainchild of Prof Mikael Hartman (Breast Cancer Surgeon at NUH) and Prof Feng Meng Ling (Assistant Professor at the Saw Swee Hock School of Public Health).
Developer of a mobile health platform designed to increase stress resilience, and attentional control, and reduce psychiatric symptoms. The company’s platform is an artificial intelligence (AI)-a native self-learning health-tech stack that contains a unique neural network for the accurate, objective, and unbiased quantification of stress via a selfie video, enabling patients to securely and privately interact through their mobile devices from anywhere in the world independently of a wearable. Our AI native remote patient monitoring and patient wellbeing support platform uses facial photoplethysmography (PPG) and deep neural networks to objectively quantify how well therapy works for each patient, and personalises safe and effective treatments accordingly. The resulting “measure-treat-measure” system has been clinically demonstrated to reduce anxiety, depression, and stress across the full severity spectrum of mental illness in a multitude of randomised controlled trials.
Developer of a chronic respiratory wellness device designed for asthmatic patients. The company’s device records important and relevant historical data regarding respiratory symptoms and medication intake to facilitate the early detection of cardiopulmonary abnormalities remotely and in real-time, enabling patients to receive fast and targeted care from the ease of their homes.
Developer of an artificial intelligence-powered diagnostic platform designed to assist doctors in analyzing microscopy images and text from patient data. The company’s platform uses artificial intelligence and natural language processing to analyze microscopy images and a patient’s medical history efficiently, enabling medical professionals to improve their efficiency in performing cancer diagnoses. Digitizing the pathology workflow from start to finish, it is a clinically approved, vendor-agnostic ecosystem equipped with a holistic range of features to support pathologists. From case management, AI analysis of whole-slide images, to report generation, it streamlines processes and helps pathologists to focus on what they do best. It opens doors to a world where telepathology and remote diagnosis is possible. With AI modules that are trained to analyze immunohistochemistry, Qritive is able to grade lymphadenopathy, breast, prostate and colon cancer, amongst other diseases, enhancing pathologists’ and physicians’ diagnostic confidence. Ultimately, it improves concordance and optimizes patient outcomes.
Operator of a machine learning platform intended to provide partners with an end-to-end resolution for cardiovascular research, development, and distribution. The company’s platform automates the manual process of measuring and interpreting echocardiograms and provides artificial intelligence-based decision support tools to save doctors time, improve clinical trials for pharma, and support the detection of routinely missed and hard-to-diagnose conditions for hospitals, enabling physicians to improve the performance of cardiovascular clinical trials.
Developer of an artificial intelligence-based healthcare platform designed to empower patients with the information they need to make healthcare decisions. The company’s platform focuses on doctor discovery, telemedicine, and cashless services and enhances the end-to-end healthcare journey, enabling patients to optimize healthcare outcomes and costs.
